extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
0db6ff3964
commit
28be216bde
5 changed files with 67 additions and 1 deletions
|
|
@ -29,6 +29,12 @@ Real-world persistence data from 125,474 commercially insured patients shows the
|
|||
|
||||
The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-15*
|
||||
|
||||
The November 2025 Medicare deal reduces GLP-1 prices to $245/month (82% below list) with $50/month out-of-pocket caps for eligible beneficiaries starting April 2026. However, eligibility is limited to ~10% of Medicare beneficiaries with specific comorbidities (BMI ≥27 + prediabetes/CVD, or BMI >30 + heart failure/hypertension/CKD). The narrow targeting may change the cost-effectiveness calculus: in high-risk patients with multiple comorbidities, the multi-organ protective effects could generate sufficient downstream savings to offset drug costs under capitated payment models, even if broader population-level impact remains inflationary.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
|
|||
|
||||
The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-15*
|
||||
|
||||
The Medicare GLP-1 deal establishes $50/month out-of-pocket maximum for tirzepatide (Zepbound) starting April 2026, and $245/month pricing for Medicare/Medicaid patients generally. This represents an 82% reduction from ~$1,350/month list prices. The deal structure directly addresses the affordability barrier that drives discontinuation in lower-income populations, providing natural experiment conditions to test whether price reduction improves persistence rates in Medicare/Medicaid populations.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -35,6 +35,12 @@ This is not a temporary shift. The 4% year-over-year growth (1.3M additional enr
|
|||
|
||||
The Special Needs Plan growth is particularly significant: SNPs grew from 14% to 21% of MA enrollment in five years, with C-SNPs (chronic condition plans) growing 71% in 2024-2025 alone. This indicates MA is not just growing through healthier beneficiaries but expanding into higher-acuity populations.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-15*
|
||||
|
||||
The Medicare GLP-1 coverage expansion creates a major test case for MA plan economics under capitation. The deal establishes $245/month pricing for Medicare patients, but the source notes that 'no clarity on whether the $245 price applies to MA plans or just traditional Medicare' and 'no details on how MA plans specifically will implement this.' Under capitation, MA plans bearing full risk would see the drug cost offset by downstream savings only if adherence is sustained in the high-risk comorbid population targeted by the narrow eligibility criteria. This creates divergent incentives between traditional Medicare (fee-for-service) and MA plans (capitated risk).
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "medicare-glp-1-coverage-expansion-uses-manufacturer-price-concessions-to-bypass-cms-rulemaking.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "narrow-eligibility-criteria-for-medicare-glp-1-coverage-target-high-risk-patients-where-cost-savings-are-most-likely.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"medicare-glp-1-coverage-expansion-uses-manufacturer-price-concessions-to-bypass-cms-rulemaking.md:set_created:2026-03-15",
|
||||
"narrow-eligibility-criteria-for-medicare-glp-1-coverage-target-high-risk-patients-where-cost-savings-are-most-likely.md:set_created:2026-03-15"
|
||||
],
|
||||
"rejections": [
|
||||
"medicare-glp-1-coverage-expansion-uses-manufacturer-price-concessions-to-bypass-cms-rulemaking.md:missing_attribution_extractor",
|
||||
"narrow-eligibility-criteria-for-medicare-glp-1-coverage-target-high-risk-patients-where-cost-savings-are-most-likely.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-15"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-11-06
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: news
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-15
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md", "medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -45,3 +49,15 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population
|
||||
EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare/Medicaid GLP-1 price: $245/month (November 2025 deal)
|
||||
- General TrumpRx price: $350/month (down from ~$1,350/month)
|
||||
- Oral Wegovy: $149-$299/month (launching January 2026)
|
||||
- Medicare beneficiary out-of-pocket cap for tirzepatide: $50/month (starting April 2026)
|
||||
- Medicare GLP-1 payment demonstration starts July 2026
|
||||
- BALANCE Model in Medicaid starts May 2026
|
||||
- BALANCE Model in Medicare Part D starts January 2027
|
||||
- Estimated eligible Medicare population: ~10% of beneficiaries
|
||||
- Eligibility: BMI ≥27 with prediabetes or CVD history, OR BMI >30 with heart failure, uncontrolled hypertension, or CKD
|
||||
|
|
|
|||
Loading…
Reference in a new issue